BioArctic AB (publ)

SSE:BIOA-B.ST

227.8 (SEK) • At close February 20, 2024
Bedrijfsnaam BioArctic AB (publ)
Symbool BIOA-B.ST
Munteenheid SEK
Prijs 227.8
Beurswaarde 16,779,748,000
Dividendpercentage 0%
52-weken bereik 191.5 - 392
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gunilla Osswald Ph.D.
Website https://www.bioarctic.se

An error occurred while fetching data.

Over BioArctic AB (publ)

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and

Vergelijkbare Aandelen

Xvivo Perfusion AB (publ) logo

Xvivo Perfusion AB (publ)

XVIVO.ST

282 SEK

Surgical Science Sweden AB (publ) logo

Surgical Science Sweden AB (publ)

SUS.ST

179.1 SEK

BICO Group AB (publ) logo

BICO Group AB (publ)

BICO.ST

45.4 SEK

CellaVision AB (publ) logo

CellaVision AB (publ)

CEVI.ST

257 SEK

Calliditas Therapeutics AB (publ) logo

Calliditas Therapeutics AB (publ)

CALTX.ST

107.8 SEK

Ambea AB (publ) logo

Ambea AB (publ)

AMBEA.ST

57.2 SEK

Attendo AB (publ) logo

Attendo AB (publ)

ATT.ST

37.8 SEK

Bonesupport Holding AB (publ) logo

Bonesupport Holding AB (publ)

BONEX.ST

189.8 SEK

BioGaia AB (publ) logo

BioGaia AB (publ)

BIOG-B.ST

124.4 SEK

Probi AB (publ) logo

Probi AB (publ)

PROB.ST

203 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)